Mild thylakoid proliferative IgA nephropathy generally cannot be cured, and can only be achieved by alleviating the symptoms of hematuria and proteinuria to maintain renal function. IgA nephropathy is a chronic progressive disease, and risk factor assessment is very important for the selection of treatment options. Risk factor assessment includes blood pressure, proteinuria and glomerular filtration rate. Reduction of proteinuria and hematuria is the basis of the treatment of IgA nephropathy, including ACEI/ARBs such as chlosartan, valsartan, captopril, enalapril, etc., hormones and/or immunosuppressants. In addition to this, IgA nephropathy is often exacerbated by upper respiratory tract infections, and aggressive treatment and removal of foci of oropharyngeal infections may be beneficial in reducing recurrent episodes of sarcoid hematuria. Suffering from mild thylakoid proliferative IgA nephropathy should go to the hospital for regular review, to clarify the condition, and to be treated under the guidance of professional physicians, so as not to delay the condition.